BRCA2 and triple-negative breast carcinoma: The results in this study are consistent with that in other cohorts of triple-negative breast cancer patients, in whom 11% to 39% have germline mutations in BRCA1 and BRCA2 [3,6,20-23], and cohorts of estrogen-receptor-negative breast cancer patients, of whom 24% to 29% have germline mutations in BRCA1 and BRCA2 [4,6,24,25].